Klinic Accepts Insurance and Handles Prior Authorization A major obstacle in accessing GLP-1 weight loss treatments is often insurance coverage
Treatment should only be continued if there has been a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0%) and weight loss of at least 3% of initial body weight
In particular, evidence suggests that the BA transporter TauT likely exerts an important role in the observed changes during supplementation
Helpful strategies include: Eat small, frequent meals Even if hunger cues are reduced, try to eat regularly throughout the day
Sikiric's lab in Croatia) No independent replication No competing research Raises red flags about bias Human data: ONE small retrospective study (not a randomized trial) No large-scale clinical trials No safety studies Unknown dosing Unknown side effects Recent systematic review (2024): Published in orthopaedic literature, concluded: "BPC-157 has potential based on preclinical data, but there is a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without publication." Reported Side Effects (From Online Users): Anonymous reports include: Injection site pain and swelling Joint pain Anxiety and panic attacks Heart palpitations Insomnia or drowsiness Fatigue and weakness Loss of appetite Depression and anhedonia (inability to feel pleasure) Note: These are anecdotal, not from clinical trials
This is why many people who start a glutathione routine for energy or immunity notice "side effects" like shinier hair or a more even skin tone